Skip to main content

Recurrent Neural Network to Predict Renal Function Impairment in Diabetic Patients via Longitudinal Routine Check-up Data

  • Conference paper
  • First Online:
Artificial Intelligence in Medicine (AIME 2021)

Abstract

People affected by diabetes are at a high risk of developing diabetic nephropathy, which, in turn, is the leading cause of end-stage chronic kidney disease worldwide. Predicting the onset of renal complications as early as possible, when kidney function is still intact, is of paramount importance for therapy selection due to existence of a class of antidiabetic agents (SGLT2 inhibitors) with known nephroprotective properties.

In the present work, we study the anthropometric and laboratory data of 28,955 diabetic patients followed for a median of 6.6 years (IQR 4.7–7.8) by 14 Italian diabetes outpatient clinics. We develop a deep learning model, based on the incorporation of variable-length longitudinal baseline data via recurrent layers, to predict the onset of impaired kidney function (KDOQI stage ≥ 3). We adopt a multi-label output-coding system to address the irregularity and sparsity in the sampling of endpoints induced by the real-life structure of the data.

Using the cumulative/dynamic AUROC with respect to a variable prediction horizon of 1 to 7 years, we compare the proposed model against the predictor of imminent deterioration of kidney function used in clinical practice, i.e., the estimated glomerular filtration rate (eGFR), and a set of year-specific logistic regressions trained on a single baseline visit.

The proposed deep learning model generally outperforms both benchmarks, especially in the medium-to-long term, with AUROC ranging from 0.841 to 0.895. Supplementary analyses confirm the effective encoding of sequence data within the network.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Koye, D.N., Magliano, D.J., Nelson, R.G., Pavkov, M.E.: The global epidemiology of diabetes and kidney disease. Adv. Chron. Kidney Dis. 25, 121–132 (2018). https://doi.org/10.1053/j.ackd.2017.10.011

    Article  Google Scholar 

  2. Ene-Iordache, B., et al.: Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Global Health 4, e307–e319 (2016). https://doi.org/10.1016/S2214-109X(16)00071-1

    Article  Google Scholar 

  3. Lin, Y.-C., Chang, Y.-H., Yang, S.-Y., Wu, K.-D., Chu, T.-S.: Update of pathophysiology and management of diabetic kidney disease. J. Formosan Med. Assoc. 117, 662–675 (2018). https://doi.org/10.1016/j.jfma.2018.02.007

    Article  Google Scholar 

  4. Andrésdóttir, G., et al.: Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diab. Care 37, 1660–1667 (2014). https://doi.org/10.2337/dc13-2036

    Article  Google Scholar 

  5. Tuttle, K.R., et al.: SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the national kidney foundation. Diabetes 70, 1–16 (2021). https://doi.org/10.2337/dbi20-0040

    Article  Google Scholar 

  6. Perkovic, V., et al.: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. (2019). https://doi.org/10.1056/NEJMoa1811744

    Article  Google Scholar 

  7. Wanner, C., et al.: Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016). https://doi.org/10.1056/NEJMoa1515920

    Article  Google Scholar 

  8. Neal, B., et al.: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017). https://doi.org/10.1056/NEJMoa1611925

    Article  Google Scholar 

  9. Yin, W.L., Bain, S.C., Min, T.: The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes. Diab. Ther. 11, 835–844 (2020). https://doi.org/10.1007/s13300-020-00798-x

    Article  Google Scholar 

  10. Ravizza, S., et al.: Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data. Nat. Med. 25, 57–59 (2019). https://doi.org/10.1038/s41591-018-0239-8

    Article  Google Scholar 

  11. Yang, C., Kong, G., Wang, L., Zhang, L., Zhao, M.-H.: Big data in nephrology: Are we ready for the change? Nephrology 24, 1097–1102 (2019). https://doi.org/10.1111/nep.13636

    Article  Google Scholar 

  12. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39, S1–266 (2002)

    Google Scholar 

  13. Gal, Y., Ghahramani, Z.: A theoretically grounded application of dropout in recurrent neural networks. arXiv:1512.05287 [stat]. (2016)

  14. Bansal, A., Heagerty, P.J.: A tutorial on evaluating the time-varying discrimination accuracy of survival models used in dynamic decision making. Med. Decis. Making 38, 904–916 (2018). https://doi.org/10.1177/0272989X18801312

    Article  Google Scholar 

  15. Mayer, G., et al.: Systems biology-derived biomarkers to predict progression of renal function decline in type 2 diabetes. Diab. Care 40, 391–397 (2017). https://doi.org/10.2337/dc16-2202

    Article  Google Scholar 

  16. DeLong, E.R., DeLong, D.M., Clarke-Pearson, D.L.: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–845 (1988). https://doi.org/10.2307/2531595

    Article  Google Scholar 

  17. Dagliati, A., et al.: Machine learning methods to predict diabetes complications. J. Diab. Sci Technol. 12, 295–302 (2018). https://doi.org/10.1177/1932296817706375

    Article  Google Scholar 

  18. Retnakaran, R., Cull, C.A., Thorne, K.I., Adler, A.I., Holman, R.R.: Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective diabetes study 74. Diabetes 55, 1832–1839 (2006). https://doi.org/10.2337/db05-1620

  19. Gers, F.A., Schmidhuber, J., Cummins, F.: Learning to forget: continual prediction with LSTM. Neural Comput. 12, 2451–2471 (1999)

    Article  Google Scholar 

Download references

Acknowledgments

This work was partly supported by MIUR (Italian Ministry for Education) under the initiative “Departments of Excellence” (Law 232/2016).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Barbara Di Camillo .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

Longato, E., Fadini, G.P., Sparacino, G., Avogaro, A., Di Camillo, B. (2021). Recurrent Neural Network to Predict Renal Function Impairment in Diabetic Patients via Longitudinal Routine Check-up Data. In: Tucker, A., Henriques Abreu, P., Cardoso, J., Pereira Rodrigues, P., Riaño, D. (eds) Artificial Intelligence in Medicine. AIME 2021. Lecture Notes in Computer Science(), vol 12721. Springer, Cham. https://doi.org/10.1007/978-3-030-77211-6_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-77211-6_37

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-77210-9

  • Online ISBN: 978-3-030-77211-6

  • eBook Packages: Computer ScienceComputer Science (R0)

Publish with us

Policies and ethics